Well, soon after that posting, the FDA told Exact that it wanted the company to seek formal regulatory approval for its diagnostic test. That sent the stock reeling, because it signals more delays and setbacks for Pregen-Plus, which has already been hit with years of delays and setbacks.
I view Exact with the same lens as a company like Discovery Labs (DSCO - Get Report), i.e., train wrecks that might, perhaps, possibly, eventually, one day turn themselves around. But there's no guarantee, and the track record certainly shouldn't give anyone confidence that the carnage can be cleaned up.
It seems better to sit on the sidelines and wait for something good to happen.
Manuel E. writes: "I am from Portugal. I appreciate very much your articles, they are informative enough and your opinions are wise. Thank you. Please let me know what you think about Prana Biotechnology (PRAN) and its drug against Alzheimer's disease." Thank you, Manuel. I left Prana out of my recent column looking at various Alzheimer's drugs in clinical trials. It was an accidental oversight on my part. The company recently announced that patient-dosing in a phase IIa study of its drug PBT-2 is finishing up, with data expected in the first quarter of 2008. I don't have an opinion on PBT-2; we'll see what the data from this trial tell us. My friend Harry Tracy, editor and publisher of the NeuroInvestment newsletter, however, isn't a big fan.